Kurt Schrader sold Allergan / (AGN) (AGN)
Kurt Schrader (D-OR), a U.S. Representative, has disclosed 1 trade in Allergan / (AGN) (AGN) since 2014, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Kurt Schrader sold $1,000 - $15,000 of Allergan / (AGN) (AGN) on March 28, 2014. Since that trade, AGN is down -42.30% against the S&P 500 up +390.11%, an outperformance of -432.41%.
Data updated
Kurt Schrader's AGN trades vs the price
AGN is down -42.30% since Kurt Schrader sold on March 28, 2014, versus +390.11% for the S&P 500.
Performance since this trade
All Kurt Schrader AGN trades
Kurt Schrader & AGN trading FAQ
Is it legal for Kurt Schrader to trade Allergan / (AGN) (AGN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Allergan / (AGN) (AGN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Kurt Schrader sell AGN?
Kurt Schrader disclosed a sale of $1,000 - $15,000 of Allergan / (AGN) (AGN) on March 28, 2014, according to public STOCK Act filings.
How has AGN performed since Kurt Schrader's trade?
Since Kurt Schrader sold AGN on March 28, 2014, the stock is down -42.30%, versus +390.11% for the S&P 500 over the same period, an outperformance of -432.41%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AGN trades?
Quantellect tracks every disclosed congressional trade in Allergan / (AGN) (AGN) on the Allergan / (AGN) congressional trading page, which aggregates filings across all members of Congress.
Kurt Schrader's AGN tradesAll congressional filings for Allergan / (AGN)Kurt Schrader's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.